News

CohBar IDs Peptide to Advance in Testing as Possible IPF Treatment

CohBar has chosen CB5138-3 as its lead treatment candidate for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, based on its promising safety, efficacy, and drug-like properties in preclinical studies. The company is planning to further test this peptide — a small protein fragment — in early studies…

Peptide-coated Nanoparticles Limit Damage of IPF, Early Study Finds

Tiny particles, or nanoparticles, coated with a peptide called GSE4 prevented some features of idiopathic pulmonary fibrosis (IPF) and eased others in a rat model of this disease, scientists report. No harmful effects were associated with the use of these GSE4-loaded nanoparticles in the animals, the team added, suggesting they should…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums